Emerging Therapies And Portfolio Expansion Will Shape Future Markets

Published
28 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$183.00
35.7% undervalued intrinsic discount
14 Aug
US$117.67
Loading
1Y
3.0%
7D
6.2%

Author's Valuation

US$183.0

35.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 1.27%

Shared on30 Apr 25
Fair value Decreased 1.49%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.26%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.26%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 1.74%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 1.46%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 0.58%

AnalystConsensusTarget has decreased revenue growth from 5.8% to 5.0%.